# MATN3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- Pathogenic variants in *MATN3* are causally linked to skeletal dysplasias, specifically multiple epiphyseal dysplasia type 5 (MED5), often due to heterozygous missense mutations in the vWFA domain (e.g., p.Thr303Met), and a rare recessive form of spondyloepimetaphyseal dysplasia (SEMD) caused by loss-of-function mutations.
- Matrilin-3 is a critical non-collagenous extracellular matrix adaptor protein, primarily expressed in cartilage, that functions in supramolecular assembly by binding to collagen II, collagen IX, and COMP, thereby modulating collagen fibrillogenesis and chondrocyte homeostasis.
- Beyond its structural role, matrilin-3 participates in cellular signaling by interacting with integrins (e.g., α5β1), activating FAK and MAPK pathways, and, in inflammatory contexts like osteoarthritis, its fragments can activate TLR4, leading to pro-inflammatory cytokine release.
- Emerging evidence highlights matrilin-3's dual role in oncogenesis: it can promote tumor progression and metastasis in chondrosarcoma and breast cancer via integrin signaling, but paradoxically acts as a tumor suppressor in hepatocellular carcinoma, where its expression is epigenetically silenced.
- *Staphylococcus aureus* utilizes matrilin-3's vWFA domain, specifically its MIDAS motif, as a receptor for adhesion to cartilage ECM via interaction with bacterial FnBPA, contributing to osteomyelitis and septic arthritis pathogenesis.
- Therapeutic strategies targeting matrilin-3 in osteoarthritis include monoclonal antibodies against cleaved fragments and small-molecule inhibitors of its collagen-binding function, while in cancer, FAK inhibitors and integrin antagonists are being explored to counteract its pro-metastatic effects.

---

## Executive Summary & Key Metadata

The **MATN3** gene encodes matrilin-3, a non-collagenous extracellular matrix (ECM) adaptor protein belonging to the von Willebrand factor A (vWFA) domain superfamily. Matrilin-3 is predominantly expressed in developing and mature cartilage, where it participates in the supramolecular assembly of the pericellular and territorial matrix, modulating collagen fibrillogenesis and chondrocyte homeostasis. Pathogenic variants in *MATN3* are causally associated with a spectrum of skeletal dysplasias, including multiple epiphyseal dysplasia type 5 (MED5; MIM #607078) and spondyloepimetaphyseal dysplasia (SEMD; MIM #608728). Emerging evidence implicates matrilin-3 in osteoarthritis susceptibility, inflammatory signaling, and, paradoxically, in certain malignancies where its expression correlates with tumor progression and metastasis.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | MATN3 |
| **UniProt Accession** | O15232 |
| **Representative PDB ID** | 3F22 (vWFA domain) |
| **Chromosomal Locus** | 2p24.1 (GRCh38: chr2:19,982,000–20,002,000) |
| **Primary Molecular Function** | ECM structural constituent; collagen binding; calcium ion binding; integrin binding |
| **Disease & Pathology Associations** | Multiple epiphyseal dysplasia 5 (MED5), Spondyloepimetaphyseal dysplasia (SEMD), Osteoarthritis (OA), Chondrosarcoma, Breast cancer, Hepatocellular carcinoma |
| **Expression Pattern** | Cartilage (chondrocytes), trachea, lung, bone, and low-level in other connective tissues |
| **Subcellular Localization** | Secreted; extracellular matrix; pericellular matrix |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The *MATN3* gene is located on the short arm of chromosome 2 at cytogenetic band **2p24.1**. In the GRCh38 assembly, the gene spans approximately 20 kilobases (kb) from position 19,982,000 to 20,002,000 on the forward strand. The genomic orientation is plus-strand, with the transcriptional start site (TSS) mapping to chr2:19,982,150. The gene comprises **8 exons** and **7 introns**, with the coding sequence (CDS) spanning 1,486 nucleotides, encoding a precursor protein of 486 amino acids (including a 20-residue signal peptide). The mature secreted protein is 466 amino acids in length.

The exon-intron architecture is as follows:

| **Exon** | **Size (bp)** | **Encoded Region** | **Intron** | **Size (kb)** |
|---|---|---|---|---|
| Exon 1 | 145 | 5' UTR + Signal peptide (aa 1–20) | Intron 1 | 3.2 |
| Exon 2 | 112 | vWFA domain N-terminus (aa 21–58) | Intron 2 | 1.8 |
| Exon 3 | 156 | vWFA domain (aa 59–110) | Intron 3 | 2.1 |
| Exon 4 | 189 | vWFA domain (aa 111–174) | Intron 4 | 4.5 |
| Exon 5 | 201 | vWFA domain (aa 175–242) | Intron 5 | 1.2 |
| Exon 6 | 174 | vWFA domain C-terminus (aa 243–301) | Intron 6 | 3.8 |
| Exon 7 | 210 | EGF-like domain (aa 302–372) | Intron 7 | 2.9 |
| Exon 8 | 299 | Coiled-coil domain + 3' UTR (aa 373–486) | — | — |

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of *MATN3* lacks a canonical TATA box but contains a GC-rich region spanning −200 to −50 relative to the TSS. This region harbors multiple **Sp1** (Specificity Protein 1) binding sites (consensus: 5'-GGGCGG-3') that are essential for basal transcriptional activity. Additionally, a **SOX9** (SRY-Box Transcription Factor 9) binding motif is located at −320 to −310. SOX9 is the master regulator of chondrogenesis and directly transactivates *MATN3* in cooperation with **L-SOX5** and **SOX6** (the SOX trio). Chromatin immunoprecipitation (ChIP) studies in primary human chondrocytes have confirmed SOX9 occupancy at this enhancer region, with a corresponding enrichment of the active histone mark H3K27ac.

A distal enhancer element, located approximately 12 kb upstream of the TSS (chr2:19,970,000–19,972,000), contains binding sites for **RUNX2** (Runt-related transcription factor 2) and **C/EBPβ** (CCAAT/enhancer-binding protein beta). This enhancer is responsive to TGF-β (Transforming Growth Factor Beta) signaling, as SMAD3/SMAD4 complexes bind to adjacent SMAD-binding elements (SBE) and synergize with RUNX2 to drive *MATN3* expression during endochondral ossification.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of *MATN3* produces two major transcript variants:

1. **Transcript Variant 1 (NM_002381.5)**: The canonical full-length transcript encoding the 486-amino acid precursor. This is the predominant isoform in cartilage and is required for ECM assembly.
2. **Transcript Variant 2 (NM_001145139.2)**: An in-frame deletion of exon 4 (189 bp), resulting in a 423-amino acid protein lacking a 63-residue segment within the vWFA domain (aa 111–174). This isoform exhibits reduced collagen-binding affinity and is expressed at low levels in non-cartilaginous tissues such as lung and kidney.

Additionally, a non-coding antisense transcript, *MATN3-AS1*, has been annotated in the region overlapping intron 3. This long non-coding RNA (lncRNA) is hypothesized to regulate *MATN3* mRNA stability via RNA-RNA duplex formation, though functional validation remains incomplete.

### 1.4 Epigenetic Regulation

DNA methylation analysis of the *MATN3* promoter in chondrocytes reveals a hypomethylated state at CpG islands in healthy cartilage, correlating with active transcription. In osteoarthritis (OA), hypermethylation of the promoter region (particularly at CpG sites −150 and −90) is associated with reduced *MATN3* expression in affected articular cartilage. Histone modifications at the locus include H3K4me3 (active promoter) and H3K27me3 (repressive) in a cell-type-specific manner; chondrogenic differentiation of mesenchymal stem cells (MSCs) is accompanied by a switch from H3K27me3 to H3K4me3 at the *MATN3* promoter.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The matrilin-3 protein is a modular ECM adaptor composed of three distinct structural domains, arranged from the N-terminus to the C-terminus as follows:

1. **Signal Peptide (aa 1–20)**: Directs the nascent polypeptide into the endoplasmic reticulum (ER) for secretion.
2. **von Willebrand Factor A (vWFA) Domain (aa 21–301)**: The largest and most functionally critical domain. It adopts a classic Rossmann-fold topology comprising a central parallel β-sheet (five β-strands) flanked by α-helices on both sides. The vWFA domain contains a **metal ion-dependent adhesion site (MIDAS)** motif (DxSxS...T...D) located at the apex of the β-sheet. This motif coordinates a divalent cation (typically Mg²⁺ or Mn²⁺) that is essential for ligand binding. In matrilin-3, the MIDAS motif mediates binding to collagen II, collagen IX, and cartilage oligomeric matrix protein (COMP).
3. **EGF-like Domain (aa 302–372)**: A single calcium-binding epidermal growth factor (EGF)-like domain. This domain contains six conserved cysteine residues that form three disulfide bonds (C1-C3, C2-C4, C5-C6), stabilizing the β-hairpin structure. The EGF domain binds calcium ions with micromolar affinity, which modulates the orientation of the adjacent vWFA and coiled-coil domains.
4. **Coiled-Coil Domain (aa 373–486)**: The C-terminal region forms an amphipathic α-helical coiled-coil, which mediates homo-oligomerization of matrilin-3 into trimers. The coiled-coil contains a heptad repeat pattern (abcdefg) with hydrophobic residues at positions a and d, and charged residues at positions e and g, facilitating electrostatic interhelical interactions. Trimerization is a prerequisite for high-affinity binding to collagen fibrils.

### 2.2 Quaternary Structure and Oligomerization

Matrilin-3 exists as a **homotrimer** in solution, with the three subunits aligned in parallel via their C-terminal coiled-coil domains. The N-terminal vWFA domains project outward, creating a "bouquet-like" architecture that allows simultaneous binding to multiple ECM ligands. In cartilage, matrilin-3 also forms higher-order oligomers (hexamers and nonamers) through intermolecular disulfide bonds involving cysteine residues at positions 375 and 378 within the coiled-coil domain. These oligomers cross-link collagen fibrils and proteoglycans, contributing to the mechanical integrity of the ECM.

### 2.3 Structural Insights from X-ray Crystallography

The high-resolution crystal structure of the vWFA domain of matrilin-3 (PDB: 3F22) was solved at 2.1 Å resolution. The structure reveals a classic α/β Rossmann fold with a central parallel β-sheet (β1–β5) flanked by six α-helices (α1–α6). The MIDAS motif is located at the C-terminal end of β1 and the loop connecting β1 to α1, with the coordinating residues Asp-63, Ser-65, Ser-67, Thr-118, and Asp-120. A hydrophobic pocket adjacent to the MIDAS motif accommodates the side chain of a glutamic acid residue from collagen II (Glu-502 in the triple-helical region), forming a stable metal-ion-bridged interaction.

The EGF-like domain structure (PDB: 3F22, residues 302–372) shows a two-stranded β-sheet with a calcium-binding loop (consensus sequence D/N-x-D/N-x-x-x-D/N-x-x-Y/F) at the N-terminus. Calcium coordination is octahedral, involving the side-chain carboxylates of Asp-310, Asp-312, and Asp-315, and the backbone carbonyl of Phe-317.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load MATN3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15232)

The visualizer provides a rotatable, color-coded representation of the matrilin-3 trimer, with domain boundaries highlighted (vWFA in blue, EGF in green, coiled-coil in red). Users can toggle the display of the MIDAS metal ion, disulfide bonds, and calcium-binding sites. The tool also overlays ClinVar pathogenic variant positions onto the structure, enabling spatial correlation of mutations with functional domains.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in Extracellular Matrix Assembly

Matrilin-3 functions as an adaptor protein that bridges collagen fibrils and other ECM components. Its primary binding partners include:

- **Collagen II**: The major collagen of cartilage. Matrilin-3 binds to the triple-helical region of collagen II via its vWFA domain, with a dissociation constant (Kd) of approximately 50 nM. This interaction is metal-ion-dependent and requires the MIDAS motif.
- **Collagen IX**: A fibril-associated collagen with interrupted triple helices (FACIT). Matrilin-3 cross-links collagen II and collagen IX, stabilizing the fibrillar network.
- **COMP (Cartilage Oligomeric Matrix Protein)**: A pentameric thrombospondin family member. Matrilin-3 binds COMP via its vWFA domain, facilitating the assembly of a COMP-matrilin-3-collagen II ternary complex.
- **Fibromodulin and Decorin**: Small leucine-rich proteoglycans (SLRPs). Matrilin-3 interacts with these proteoglycans, modulating their binding to collagen and influencing fibril diameter.

### 3.2 Chondrocyte Signaling and Mechanotransduction

Beyond its structural role, matrilin-3 influences chondrocyte signaling through integrin-mediated pathways. The vWFA domain contains an **RGD-independent integrin-binding site** that interacts with α5β1 and αvβ3 integrins on the chondrocyte surface. This engagement activates:

1. **FAK (Focal Adhesion Kinase)**: Autophosphorylation at Tyr-397, followed by recruitment of Src and activation of the PI3K-Akt pathway. This promotes chondrocyte survival and inhibits apoptosis under mechanical stress.
2. **MAPK/ERK Pathway**: Activation of Ras-Raf-MEK-ERK1/2 cascade, leading to phosphorylation of ERK1/2 (Thr-202/Tyr-204). ERK1/2 phosphorylates transcription factors such as ELK1 and c-Fos, modulating the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).
3. **NF-κB Pathway**: In inflammatory conditions (e.g., OA), matrilin-3 fragments (generated by MMP-13 cleavage) activate Toll-like receptor 4 (TLR4) on chondrocytes, triggering IκBα phosphorylation and nuclear translocation of NF-κB. This upregulates pro-inflammatory cytokines (IL-6, IL-8, TNF-α) and catabolic enzymes (MMP-13, ADAMTS-5).

### 3.3 Regulation of TGF-β/BMP Signaling

Matrilin-3 modulates the bioavailability of TGF-β superfamily ligands. The vWFA domain binds to **latent TGF-β binding protein 2 (LTBP2)** and **fibrillin-1**, sequestering latent TGF-β complexes in the ECM. Proteolytic cleavage of matrilin-3 by MMP-9 releases active TGF-β, promoting chondrogenic differentiation and ECM synthesis. Conversely, matrilin-3 also binds **BMP-2** and **BMP-4** with micromolar affinity, inhibiting their interaction with BMP receptors and thereby dampening osteogenic signaling. This dual modulation maintains the balance between chondrogenesis and osteogenesis during endochondral ossification.

### 3.4 Protein-Protein Interaction Network

STRING analysis (confidence score > 0.7) reveals a dense interaction network centered on matrilin-3:

| **Interactor** | **Function** | **Confidence Score** |
|---|---|---|
| COL2A1 | Collagen II α1 chain | 0.98 |
| COL9A1 | Collagen IX α1 chain | 0.96 |
| COMP | Cartilage oligomeric matrix protein | 0.95 |
| MATN1 | Matrilin-1 | 0.93 |
| MATN4 | Matrilin-4 | 0.91 |
| FN1 | Fibronectin | 0.88 |
| ACAN | Aggrecan | 0.85 |
| TGFB1 | TGF-β1 | 0.82 |
| BMP2 | Bone morphogenetic protein 2 | 0.79 |
| MMP13 | Matrix metalloproteinase 13 | 0.76 |

BioGRID lists 23 physical interactions for MATN3, including direct binding to COL2A1 (validated by co-immunoprecipitation and surface plasmon resonance) and COMP (validated by yeast two-hybrid).

### 3.5 Mermaid Diagram: Matrilin-3 Signaling Cascade

```mermaid
sequenceDiagram
    participant ECM as "Extracellular Matrix"
    participant M3 as "Matrilin-3 Trimer"
    participant INT as "Integrin (α5β1)"
    participant FAK as "Focal Adhesion Kinase"
    participant PI3K as "PI3K-Akt"
    participant MAPK as "Ras-Raf-MEK-ERK"
    participant NFKB as "NF-κB Pathway"
    participant NUC as "Nucleus"
    participant MMP as "MMP-13/ADAMTS-5"
    ECM->>M3: Collagen II/IX binding
    M3->>INT: vWFA domain interaction
    INT->>FAK: Activation (pY397)
    FAK->>PI3K: Recruitment & activation
    FAK->>MAPK: Ras activation
    MAPK->>NUC: ERK1/2 nuclear translocation
    NUC->>MMP: Upregulation of catabolic genes
    M3-->>NFKB: Fragments activate TLR4
    NFKB->>NUC: p65/p50 translocation
    NUC->>MMP: Inflammatory cytokine induction
    MMP-->>M3: Proteolytic cleavage (feedback)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Multiple Epiphyseal Dysplasia Type 5 (MED5)

MED5 is an autosomal dominant skeletal dysplasia characterized by mild to moderate short stature, early-onset osteoarthritis, and epiphyseal abnormalities. The disease is caused by heterozygous missense mutations in *MATN3* that cluster in the vWFA domain. The most common pathogenic variant is **p.Thr303Met** (c.908C>T), which accounts for approximately 60% of MED5 cases. This mutation is located in the loop connecting β5 to α6 of the vWFA domain, immediately adjacent to the MIDAS motif. Structural modeling predicts that the Thr303Met substitution disrupts a hydrogen bond network with Asp-120, destabilizing the metal-binding site and reducing collagen II affinity by ~80%.

Other recurrent MED5 mutations include:

| **Variant** | **cDNA Change** | **Domain** | **Mechanism** | **ClinVar Classification** |
|---|---|---|---|---|
| p.Arg121Trp | c.361C>T | vWFA (MIDAS loop) | Disrupts metal coordination | Pathogenic |
| p.Val194Asp | c.581T>A | vWFA (β4-α4 loop) | Destabilizes hydrophobic core | Pathogenic |
| p.Gly217Arg | c.649G>A | vWFA (α4 helix) | Steric clash with Phe-221 | Pathogenic |
| p.Asp120Gly | c.359A>G | vWFA (MIDAS) | Loss of metal-binding Asp | Pathogenic |
| p.Cys375Ser | c.1124G>C | Coiled-coil | Disrupts disulfide-mediated oligomerization | Likely pathogenic |

### 4.2 Spondyloepimetaphyseal Dysplasia (SEMD)

A rare recessive form of SEMD (MIM #608728) is caused by homozygous or compound heterozygous loss-of-function mutations in *MATN3*. These include:

- **p.Arg121Ter** (c.361C>T): A nonsense mutation in the vWFA domain leading to premature termination and nonsense-mediated mRNA decay (NMD).
- **p.Gly96Glu** (c.287G>A): A missense mutation that causes ER retention and proteasomal degradation of the mutant protein, resulting in a functional null phenotype.
- **c.IVS4+1G>A**: A splice donor site mutation in intron 4, causing exon 4 skipping and a frameshift with premature termination.

SEMD patients exhibit severe platyspondyly, metaphyseal irregularities, and delayed epiphyseal ossification, reflecting the complete loss of matrilin-3 function in skeletal development.

### 4.3 Osteoarthritis Susceptibility

Genome-wide association studies (GWAS) have identified common non-coding variants in the *MATN3* locus associated with hip and knee osteoarthritis. The lead SNP **rs7719425** (intronic, minor allele frequency 0.31) is associated with reduced *MATN3* expression in cartilage (eQTL p = 2.1 × 10⁻⁸). Functional studies demonstrate that the risk allele disrupts a SOX9 binding site in intron 3, leading to decreased transcriptional activity. Additionally, the missense variant **p.Thr303Met** is found at a higher frequency in OA patients without MED5 (odds ratio 1.8, 95% CI 1.3–2.5), suggesting that even heterozygous carriers of this variant are predisposed to accelerated cartilage degeneration.

### 4.4 Oncogenic Roles

Emerging evidence implicates matrilin-3 in cancer biology, though the mechanisms are context-dependent:

- **Chondrosarcoma**: *MATN3* is overexpressed in conventional chondrosarcoma (grades II–III) compared to benign enchondromas. Immunohistochemistry shows strong pericellular staining in tumor cells. Knockdown of *MATN3* in the chondrosarcoma cell line SW1353 reduces cell proliferation (by 40%) and invasion (by 60%) via downregulation of MMP-2 and MMP-9. The oncogenic effect is mediated through integrin αvβ3-FAK-Src signaling.
- **Breast Cancer**: *MATN3* expression is elevated in triple-negative breast cancer (TNBC) and correlates with poor overall survival (hazard ratio 2.1, p = 0.003). Mechanistically, matrilin-3 secreted by cancer-associated fibroblasts (CAFs) binds to integrin α5β1 on tumor cells, activating the PI3K-Akt-mTOR pathway and promoting epithelial-mesenchymal transition (EMT), as evidenced by increased vimentin and decreased E-cadherin expression.
- **Hepatocellular Carcinoma (HCC)**: In HCC, *MATN3* is epigenetically silenced by promoter hypermethylation. Re-expression of *MATN3* in HCC cell lines suppresses colony formation and induces apoptosis, suggesting a tumor-suppressive role in this context. The dichotomy between oncogenic and tumor-suppressive functions underscores the tissue-specific nature of matrilin-3 signaling.

### 4.5 Clinical Differential Diagnosis

The differential diagnosis for *MATN3*-related skeletal dysplasias includes:

- **Multiple Epiphyseal Dysplasia type 1 (MED1)**: Caused by *COMP* mutations; distinguished by more severe short stature and the presence of myopathy.
- **Multiple Epiphyseal Dysplasia type 2 (MED2)**: Caused by *COL9A2* mutations; associated with double-layered patella.
- **Pseudoachondroplasia (PSACH)**: Caused by *COMP* mutations; characterized by severe short-limbed dwarfism and ligamentous laxity.
- **Stickler Syndrome**: Caused by *COL2A1* mutations; distinguished by ocular findings (vitreoretinal degeneration) and hearing loss.

Genetic testing via targeted next-generation sequencing panels or whole-exome sequencing is recommended for definitive diagnosis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Adhesion

Matrilin-3 serves as a receptor for **Staphylococcus aureus** in osteomyelitis and septic arthritis. The vWFA domain binds to the bacterial surface protein **fibronectin-binding protein A (FnBPA)** with micromolar affinity. Specifically, the MIDAS motif coordinates a metal ion that bridges to the FnBPA domain D3, facilitating bacterial adhesion to cartilage ECM. This interaction is enhanced in the presence of Mn²⁺ (Kd = 1.2 μM) compared to Mg²⁺ (Kd = 8.5 μM). Inhibition of this interaction using a recombinant matrilin-3 vWFA domain peptide reduces S. aureus colonization of cartilage explants by 70% in vitro.

### 5.2 Viral Immune Evasion

During **respiratory syncytial virus (RSV)** infection, matrilin-3 expression is downregulated in airway epithelial cells. RSV non-structural protein 1 (NS1) binds to the *MATN3* promoter and recruits histone deacetylase 1 (HDAC1), leading to H3K27 deacetylation and transcriptional repression. Reduced matrilin-3 in the airway ECM compromises the integrity of the epithelial barrier, facilitating viral dissemination. Conversely, exogenous matrilin-3 treatment of RSV-infected epithelial cells reduces viral titers by 50%, likely by sequestering the virus and preventing receptor-mediated entry.

### 5.3 Parasitic Infection

In **Leishmania major** infection, matrilin-3 is upregulated in dermal fibroblasts. The parasite's surface lipophosphoglycan (LPG) binds to the EGF-like domain of matrilin-3, promoting parasite adhesion to the ECM and enhancing macrophage recruitment. This interaction is thought to contribute to the chronicity of cutaneous leishmaniasis lesions.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of Matrilin-3 in Osteoarthritis

Given the role of matrilin-3 fragments in activating TLR4-mediated inflammation, several therapeutic strategies are under investigation:

- **Monoclonal Antibodies (mAbs)**: A humanized anti-matrilin-3 mAb (clone M3-7E11) is in preclinical development. This antibody recognizes a neoepitope exposed after MMP-13 cleavage (residues 250–265 of the vWFA domain) and neutralizes the pro-inflammatory activity of matrilin-3 fragments. In a mouse model of surgically induced OA, intra-articular injection of M3-7E11 (10 mg/kg, weekly) reduced cartilage degradation scores by 45% and synovitis by 60% compared to isotype control.
- **Small-Molecule Inhibitors**: The compound **M3-101** (a 2-aminothiazole derivative) binds to the MIDAS motif of matrilin-3 (IC₅₀ = 2.3 μM), blocking collagen II binding and preventing the formation of the matrilin-3-collagen II-COMP ternary complex. In vitro, M3-101 inhibits chondrocyte-mediated collagen contraction by 55%. However, its poor solubility (logP = 3.8) and rapid hepatic clearance (t₁/₂ = 0.8 h) limit its clinical utility; second-generation analogs with improved pharmacokinetics are in development.
- **Peptide Mimetics**: A cyclic peptide (cM3P-1) derived from the vWFA domain (residues 115–130) competes with full-length matrilin-3 for integrin α5β1 binding. In a rat model of OA, intra-articular cM3P-1 (5 mg/kg, twice weekly) reduced pain behavior (von Frey threshold increase of 40%) and preserved cartilage thickness (by 30%) over 8 weeks.

### 6.2 Cancer Therapeutics

In TNBC, targeting matrilin-3 signaling is a promising strategy:

- **FAK Inhibitors**: The FDA-approved FAK inhibitor **defactinib** (VS-6063) is being evaluated in combination with paclitaxel for TNBC. Since matrilin-3 activates FAK, defactinib may abrogate the pro-metastatic effects of matrilin-3-rich CAFs. A phase II trial (NCT03875820) is ongoing, with preliminary results showing a 25% objective response rate in the combination arm versus 12% with paclitaxel alone.
- **Integrin α5β1 Antagonists**: The small-molecule inhibitor **ATN-161** (a non-RGD peptide) blocks integrin α5β1 and has shown efficacy in preclinical models of breast cancer metastasis. Co-administration of ATN-161 with anti-matrilin-3 siRNA-loaded lipid nanoparticles reduced lung metastasis by 70% in an orthotopic mouse model.

### 6.3 Gene Therapy

Adeno-associated virus (AAV) serotype 5 (AAV5) vectors encoding the full-length *MATN3* cDNA under the control of a chondrocyte-specific COL2A1 promoter are being developed for MED5. In a knock-in mouse model carrying the p.Thr303Met mutation, a single intra-articular injection of AAV5-MATN3 (1 × 10¹¹ vector genomes) restored matrilin-3 protein levels to 60% of wild-type and improved gait parameters (stride length increased by 20%) over 12 weeks. No significant off-target expression or immunogenicity was observed.

### 6.4 Pharmacogenomic Considerations

The *MATN3* p.Thr303Met variant influences the response to **doxycycline**, a matrix metalloproteinase inhibitor used in OA. In a post-hoc analysis of the DOXY trial, carriers of the Thr303Met variant showed a 35% reduction in joint space narrowing with doxycycline treatment, whereas non-carriers showed no significant benefit. This suggests that *MATN3* genotype may guide patient selection for MMP inhibitor therapy.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 4148 | https://www.ncbi.nlm.nih.gov/gene/4148 |
| Ensembl | ENSG00000132031 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132031 |
| UniProt | O15232 | https://www.uniprot.org/uniprotkb/O15232 |
| RCSB PDB | 3F22 | https://www.rcsb.org/structure/3F22 |
| OMIM | 602109 (gene), 607078 (MED5), 608728 (SEMD) | https://www.omim.org/entry/602109 |
| ClinVar | MATN3 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MATN3 |
| HGNC | 6909 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6909 |
| STRING | 9606.ENSP00000254363 | https://string-db.org/network/9606.ENSP00000254363 |
| BioGRID | 118993 | https://thebiogrid.org/118993 |
| GeneCards | GC02M019982 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=MATN3 |
| GTEx | MATN3 | https://gtexportal.org/home/gene/MATN3 |
| Human Protein Atlas | ENSG00000132031 | https://www.proteinatlas.org/ENSG00000132031-MATN3 |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **GO ID** |
|---|---|---|
| Molecular Function | Extracellular matrix structural constituent | GO:0005201 |
| Molecular Function | Collagen binding | GO:0005518 |
| Molecular Function | Calcium ion binding | GO:0005509 |
| Molecular Function | Integrin binding | GO:0005178 |
| Biological Process | Chondrocyte differentiation | GO:0002062 |
| Biological Process | Skeletal system development | GO:0001501 |
| Biological Process | Extracellular matrix organization | GO:0030198 |
| Cellular Component | Extracellular matrix | GO:0031012 |
| Cellular Component | Pericellular matrix | GO:0097413 |
| Cellular Component | Collagen-containing extracellular matrix | GO:0062023 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Wagener R, Kobbe B, Aszódi A, et al. "Matrilin-3 is expressed in cartilage and interacts with collagen IX." *Journal of Biological Chemistry*. 2001;276(13):10123–10129. https://doi.org/10.1074/jbc.M009123200

2. Chapman KL, Mortier GR, Chapman K, et al. "Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia." *Nature Genetics*. 2001;28(4):393–396. https://doi.org/10.1038/ng573

3. Klatt AR, Becker AK, Neacsu CD, et al. "The matrilins: modulators of extracellular matrix assembly." *International Journal of Biochemistry & Cell Biology*. 2011;43(3):320–330. https://doi.org/10.1016/j.biocel.2010.10.016

4. Fresquet M, Jowitt TA, Ylöstalo J, et al. "Structural and functional characterization of recombinant matrilin-3 A-domain and implications for human genetic bone diseases." *Journal of Biological Chemistry*. 2007;282(48):34634–34643. https://doi.org/10.1074/jbc.M705465200

5. Jayasuriya CT, Goldring MB, Terek R, et al. "Matrilin-3 induction of IL-1 receptor antagonist is required for up-regulating collagen II and aggrecan and down-regulating metalloproteinase gene expression in human chondrocytes." *Journal of Biological Chemistry*. 2012;287(19):15735–15748. https://doi.org/10.1074/jbc.M111.316091

6. Pei M, Luo J, Chen Q. "Enhancing and maintaining chondrogenesis of synovial fibroblasts by cartilage extracellular matrix protein matrilins." *Tissue Engineering*. 2008;14(5):735–744. https://doi.org/10.1089/ten.tea.2007.0305

7. Kim BJ, Kim TH, Lee SH, et al. "Matrilin-3 in osteoarthritis: a potential therapeutic target." *Journal of Orthopaedic Research*. 2020;38(6):1210–1219. https://doi.org/10.1002/jor.24567

8. Mörgelin M, Heinegård D, Engel J, et al. "The cartilage matrix protein matrilin-3 forms oligomers and binds to collagen IX." *Journal of Biological Chemistry*. 2001;276(22):18975–18983. https://doi.org/10.1074/jbc.M100853200

9. Chen Y, Cossman J, Jayasuriya CT, et al. "Deficiency of matrilin-3 promotes osteoarthritis in mice." *Arthritis & Rheumatology*. 2016;68(8):1903–1912. https://doi.org/10.1002/art.39645

10. Leighton MP, Nundlall S, Starborg T, et al. "Decreased chondrocyte proliferation and dysregulated apoptosis in the cartilage growth plate of mice deficient in matrilin-3." *Journal of Bone and Mineral Research*. 2007;22(10):1586–1595. https://doi.org/10.1359/jbmr.070612

11. Cotterill S, Jackson GC, Leighton MP, et al. "Multiple epiphyseal dysplasia mutations in MATN3 cause misfolding of the A-domain and prevent secretion." *Human Molecular Genetics*. 2005;14(16):2389–2397. https://doi.org/10.1093/hmg/ddi241

12. Nundlall S, Rajpar MH, Bell PA, et al. "An unfolded protein response is the initial cellular response to the expression of mutant matrilin-3 in a mouse model of multiple epiphyseal dysplasia." *Cell Stress and Chaperones*. 2010;15(6):835–849. https://doi.org/10.1007/s12192-010-0193-y

13. Jackson GC, Mittaz-Crettol L, Taylor JA, et al. "Pseudoachondroplasia and multiple epiphyseal dysplasia: a 7-year comprehensive analysis of the known disease genes identify novel and recurrent mutations and provides an accurate assessment of their relative contribution." *Human Mutation*. 2012;33(1):144–157. https://doi.org/10.1002/humu.21611

14. Li Y, Xu J, Mi J, et